Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.

Trial Details

NCT ID
NCT06390956
Phase
PHASE2
Sponsor
University of Utah
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Pirtobrutinib
  • Rituximab
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Subjects aged ≥ 18 years.
  • ECOG Performance Status ≤ 2.
  • Histologically confirmed marginal zone lymphoma, including splenic, nodal, and extranodal sub-types per the enrolling institution.
  • Subjects must have an indication for treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →